StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Revenue recognized from beginning-of-year deferred by Quarter

Revenue recognized from beginning-of-year deferred revenue balance ($M) ($M)

QuarterlyAnnual

Moderna Revenue recognized from beginning-of-year deferred: $235M in Q2 2026, up 75.4% from a year earlier.

Latest, Q2 2026
235
Period ended Jun 30, 2026
Change on a year earlier
+75.4%
134 in Q2 2025
History
24 quarters
Since Q3 2020
Sources
24
Documents cited below

Where the Q2 2026 figure comes from

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: Form 10-Q (filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Note 2 (Contract Liabilities).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRevenue recognized from beginning-of-year deferred revenue balance ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026235+75.4%Form 10-Q (filed 2026-07-31) ↗
Q1 2026Mar 31, 202653+278.6%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 202526+420.0%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 2025146+294.6%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 2025134-34.6%Form 10-Q (filed 2025-08-01) ↗
Q1 2025Mar 31, 202514-17.6%Form 10-Q (filed 2025-05-01) ↗
Q4 2024Dec 31, 20245-98.4%Form 10-K (filed 2025-02-21) ↗
Q3 2024Sep 30, 202437-58.0%Form 10-Q (filed 2024-11-07) ↗
Q2 2024Jun 30, 2024205+120.4%Form 10-Q (filed 2024-08-01) ↗
Q1 2024Mar 31, 202417-63.8%Form 10-Q (filed 2024-05-02) ↗
Q4 2023Dec 31, 2023320+527.5%Form 10-K (filed 2024-02-23) ↗
Q3 2023Sep 30, 202388-86.1%Form 10-Q (filed 2023-11-03) ↗
Q2 2023Jun 30, 202393+13.4%Form 10-Q (filed 2023-08-03) ↗
Q1 2023Mar 31, 202347-97.3%Form 10-Q (filed 2023-05-04) ↗
Q4 2022Dec 31, 202251-97.5%Form 10-K (filed 2023-02-24) ↗
Q3 2022Sep 30, 2022635-81.8%Form 10-Q (filed 2022-11-03) ↗

Breakdown

What makes up revenue recognized from beginning-of-year deferred

Cite this data

StockData. (2026). Moderna Revenue recognized from beginning-of-year deferred ($M), quarterly Q3 2020–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-recognized-beg

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.